JAZZ Q2 2019 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$534M+6.7% YoY

Gross Profit

$506M94.8% margin

Operating Income

$204M38.2% margin

Net Income

$262M49.0% margin

EPS (Diluted)

$4.56

QoQ Revenue Growth

+5.1%

Cash Flow

Operating Cash Flow

$149M

Free Cash Flow

$107M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$5.5B

Total Liabilities

$2.5B

Stockholders' Equity

$3.0B

Cash & Equivalents

$638M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$534M	$500M	+6.7%
Gross Profit	$506M	$466M	+8.7%
Operating Income	$204M	$153M	+33.3%
Net Income	$262M	$92M	+183.7%

Revenue Segments

Product And Services, Product Sales

$523M49%

Xyrem

$413M39%

Defitelio/Defibrotide

$46M4%

Vyxeos

$31M3%

Erwinaze And Erwinase

$28M3%

Product And Services, Royalties And Contract Revenue

$11M1%

Other Products

$5M0%

Geographic Segments

UNITED STATES

$481M90%

Europe

$37M7%

Other Countries

$17M3%